Seagen Tukysa Maintains Survival Benefit, Delays Cancer Progression In The Brain In Breast Cancer Patients

Seagen Inc SGEN has revealed new data from exploratory analyses from the HER2CLIMB trial of Tukysa (tucatinib) combined with trastuzumab & capecitabine in HER2-positive metastatic breast cancer with stable or active brain metastases.

• The data were featured at the 2021 San Antonio Breast Cancer Symposium.
• After a median follow-up of 29.6 months, the Tukysa regimen improved overall survival by 9.1 months compared to trastuzumab and capecitabine alone (21.6 months vs. 12.5 months). 
• The benefit extended to patients with active or stable brain metastases.
• Tukysa treatment continued to show clinically meaningful benefit in progression-free survival in the central nervous system, representing a delay of cancer progression in the brain (9.9 months versus 4.2 months). 
• The intracranial objective response rate and duration of objective response were consistent with previous analyses.
• Related Link: Seagen Bets On China's ADC In $2.6B Cancer Deal.
• Price Action: SGEN shares closed at $149.55 on Wednesday.